In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antisoma PLC

www.antisoma.com

Latest From Antisoma PLC

Stockwatch: Pandora’s Interim Analysis

The Medicines Company, Amarin and Geron have all reported interim analyses for clinical studies recently and investors have been left disappointed. Were we better off without the interim analysis?

Research & Development Business Strategies

Stockwatch: Damage Not Controlled

As financial turmoil broke out around the world in the wake of the vote for Brexit, UK pharma majors GlaxoSmithKline and AstraZeneca saw their stock rise. There's an uncertain outlook for the broader life sciences sector.

Brexit Companies

Stockwatch: My enemy's drug failure is not my drug's success

In life sciences, big share price movements occur in response to merger and acquisition (M&A) activity, clinical trial results and regulatory events. Actual, rather than rumoured M&A is the panacea for many investors but some companies have played up to this by appearing to spend more effort stoking rumours of their impending acquisition than developing their drugs. Such is the case with Achillion Pharmaceuticals, whose cry of acquisition wolf after each of its hepatitis C virus (HCV) antiviral competitors is acquired has been accompanied by a share price rise and an inevitable fundraising by the company. It is illogical for investors to believe that any and all companies developing HCV antivirals will be acquired. Those that have been repeatedly passed over as competitors with better and more advanced products are snapped up seem to be unlikely M&A candidates, but when they shout loud enough, investors behave as if this is a maximum sum game.

Gastrointestinal Cardiovascular

Takeda strengthens cancer focus with Mersana ADC deal

Takeda is ramping up its presence in oncology, having signed a deal with antibody-drug conjugate (ADC) specialist Mersana Therapeutics via subsidiary Millennium Pharmaceuticals.

Infectious Diseases Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Antisoma PLC
  • Senior Management
  • Glyn O Edwards, CEO
    Eric Dodd, CFO
    Nicholas Adams, VP, Bus. Dev.
  • Contact Info
  • Antisoma PLC
    Phone: (44) 20 3249 2100
    566 Chiswick High Road
    Building 5
    London, W4 5YF
    UK
UsernamePublicRestriction

Register